Altimmune (NASDAQ:ALT) Upgraded by The Goldman Sachs Group to Strong Sell Rating

Altimmune (NASDAQ:ALT - Get Free Report) was upgraded by stock analysts at The Goldman Sachs Group to a "strong sell" rating in a research note issued on Thursday, Marketbeat Ratings reports.

Several other research firms also recently commented on ALT. HC Wainwright reiterated a "buy" rating and issued a $12.00 price objective on shares of Altimmune in a report on Friday, June 27th. JMP Securities decreased their price objective on Altimmune from $25.00 to $15.00 and set a "market outperform" rating on the stock in a report on Thursday. Wall Street Zen downgraded Altimmune from a "hold" rating to a "sell" rating in a report on Saturday, June 14th. Finally, William Blair reiterated a "market perform" rating on shares of Altimmune in a report on Friday, June 27th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Altimmune has a consensus rating of "Moderate Buy" and a consensus target price of $18.20.

Altimmune Trading Down 7.2%

Shares of NASDAQ:ALT opened at $4.40 on Thursday. The stock has a market capitalization of $356.88 million, a P/E ratio of -3.49 and a beta of 0.47. The stock's 50-day moving average price is $5.65 and its 200-day moving average price is $5.87. Altimmune has a 12-month low of $2.90 and a 12-month high of $11.16.

Altimmune (NASDAQ:ALT - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.09. The firm had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.00 million. Altimmune had a negative return on equity of 65.44% and a negative net margin of 451,200.00%. During the same quarter in the previous year, the business earned ($0.34) earnings per share. As a group, research analysts predict that Altimmune will post -1.35 EPS for the current year.

Institutional Trading of Altimmune

Several large investors have recently bought and sold shares of the company. Barclays PLC boosted its position in Altimmune by 1.1% during the 4th quarter. Barclays PLC now owns 157,528 shares of the company's stock valued at $1,135,000 after acquiring an additional 1,787 shares in the last quarter. Rafferty Asset Management LLC boosted its position in shares of Altimmune by 1.3% in the 4th quarter. Rafferty Asset Management LLC now owns 157,750 shares of the company's stock worth $1,137,000 after purchasing an additional 1,964 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of Altimmune by 2.0% in the 4th quarter. JPMorgan Chase & Co. now owns 102,940 shares of the company's stock worth $742,000 after purchasing an additional 2,028 shares in the last quarter. Bank of New York Mellon Corp boosted its position in shares of Altimmune by 1.2% in the 1st quarter. Bank of New York Mellon Corp now owns 189,000 shares of the company's stock worth $945,000 after purchasing an additional 2,162 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Altimmune by 4.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 48,901 shares of the company's stock worth $247,000 after purchasing an additional 2,241 shares in the last quarter. 78.05% of the stock is owned by institutional investors.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.